Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Current Assets (2017 - 2025)

Historic Current Assets for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $73.6 million.

  • Innate Pharma's Current Assets fell 3879.51% to $73.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $73.6 million, marking a year-over-year decrease of 3879.51%. This contributed to the annual value of $91.6 million for FY2024, which is 4246.67% down from last year.
  • Per Innate Pharma's latest filing, its Current Assets stood at $73.6 million for Q2 2025, which was down 3879.51% from $91.6 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Current Assets registered a high of $183.3 million during Q2 2022, and its lowest value of $73.6 million during Q2 2025.
  • Moreover, its 5-year median value for Current Assets was $156.2 million (2021), whereas its average is $138.0 million.
  • As far as peak fluctuations go, Innate Pharma's Current Assets plummeted by 9990.46% in 2021, and later soared by 1737.59% in 2022.
  • Over the past 5 years, Innate Pharma's Current Assets (Quarter) stood at $158.2 million in 2021, then dropped by 9.8% to $142.7 million in 2022, then increased by 11.63% to $159.3 million in 2023, then plummeted by 42.47% to $91.6 million in 2024, then dropped by 19.72% to $73.6 million in 2025.
  • Its Current Assets was $73.6 million in Q2 2025, compared to $91.6 million in Q4 2024 and $120.2 million in Q2 2024.